Macrophage reprogramming in degenerative musculoskeletal diseases: From tissue-niche biology to therapeutic translation
4 affiliations
- 1Orthopaedic Trauma Service Center, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050011, China
- 2School of Life Science, Beijing Institute of Technology, Beijing, 100081, China
- 3School of Life Science, Beijing Institute of Technology, Beijing, 100081, China; Corresponding author.
- 4Orthopaedic Trauma Service Center, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050011, China; Corresponding author.
Abstract
Degenerative musculoskeletal diseases (DMSDs), including osteoarthritis (OA), osteoporosis (OP), intervertebral disc degeneration (IVDD), and sarcopenia (SP), impose a major burden through pain, structural deterioration, mobility loss, fracture risk, and functional decline. Although these disorders are often grouped as age-related musculoskeletal conditions, they arise from distinct tissue niches and cannot be explained by a single pathogenic mechanism. Macrophages occupy a central position at the interface between degenerative stress and tissue outcome, but their functions extend far beyond a binary M1/M2 polarization model. This Review proposes a disease-niche-adapted framework for macrophage reprogramming in DMSDs. In this framework, macrophages are interpreted according to the pathological tasks they perform within each tissue environment: inflammatory amplification and pain-related synovial crosstalk in OA, osteoimmune remodeling in OP, immune-barrier disruption and macrophage-nucleus pulposus (NP) cell feedback in IVDD, and impaired regenerative support in aging muscle in SP. We discuss how macrophage functional states are shaped by transcriptional and epigenetic regulation, immunometabolic rewiring, inflammatory signaling, autophagy and organelle quality control, and local niche-derived cues. Therapeutic strategies are then evaluated according to whether they interrupt upstream niche stress, redirect inflammatory and metabolic decoding, restore quality-control capacity, or reshape macrophage-mediated tissue communication. Finally, we propose that macrophage-targeted therapy should be assessed through a hierarchy of evidence, progressing from marker changes to functional reprogramming, macrophage-causal validation, and disease-specific structural or functional improvement. This framework may help convert macrophage plasticity from a broad immunological concept into a more precise, testable, and disease-adapted therapeutic strategy for musculoskeletal degeneration. The translational potential of this article: This Review provides a disease-niche-adapted framework for evaluating macrophage reprogramming in degenerative musculoskeletal diseases. By linking disease-specific macrophage tasks with regulatory mechanisms, therapeutic entry points, causal validation, delivery feasibility, and tissue-relevant endpoints, this framework may help guide both the design and translational assessment of macrophage-targeted interventions for musculoskeletal degeneration.
Related
- Rewiring the breast cancer immune microenvironment through non-coding RNA-macrophage crosstalk: therapeutic vulnerabilities for immune reprogramming
- CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis
- Host Metabolic Reprogramming Defines Macrophage Antifungal Activity Against Cryptococcus neoformans
- Mesaconate-Based Polyester Nanoparticles Reveal How Metabolite Isomerism Shapes Polymer Behavior, Macrophage Reprogramming, and Systemic Immunomodulation
- PPARγ brakes cytosolic DNA-induced macrophage inflammation by super-enhancer metabolic reprogramming
BibTeX
@article{wang2026macrophage,
title = {{Macrophage reprogramming in degenerative musculoskeletal diseases: From tissue-niche biology to therapeutic translation}},
author = {Chao Wang and Yuxin Chen and Dong Ren and Yufeng Chen and Guowei Ren and Tong Li and Mehboob Ullah and Qin Xia and Lei Dong and Pengcheng Wang},
journal = {Journal of Orthopaedic Translation},
year = {2026},
month = oct,
doi = {10.1016/j.jot.2026.101244},
url = {https://doi.org/10.1016/j.jot.2026.101244},
note = {CC BY},
}
RIS
TY - JOUR
TI - Macrophage reprogramming in degenerative musculoskeletal diseases: From tissue-niche biology to therapeutic translation
AU - Chao Wang
AU - Yuxin Chen
AU - Dong Ren
AU - Yufeng Chen
AU - Guowei Ren
AU - Tong Li
AU - Mehboob Ullah
AU - Qin Xia
AU - Lei Dong
AU - Pengcheng Wang
PY - 2026
DA - 2026/10/24
JO - Journal of Orthopaedic Translation
DO - 10.1016/j.jot.2026.101244
UR - https://doi.org/10.1016/j.jot.2026.101244
AB - Degenerative musculoskeletal diseases (DMSDs), including osteoarthritis (OA), osteoporosis (OP), intervertebral disc degeneration (IVDD), and sarcopenia (SP), impose a major burden through pain, structural deterioration, mobility loss, fracture risk, and functional decline. Although these disorders are often grouped as age-related musculoskeletal conditions, they arise from distinct tissue niches and cannot be explained by a single pathogenic mechanism. Macrophages occupy a central position at the interface between degenerative stress and tissue outcome, but their functions extend far beyond a binary M1/M2 polarization model. This Review proposes a disease-niche-adapted framework for macrophage reprogramming in DMSDs. In this framework, macrophages are interpreted according to the pathological tasks they perform within each tissue environment: inflammatory amplification and pain-related synovial crosstalk in OA, osteoimmune remodeling in OP, immune-barrier disruption and macrophage-nucleus pulposus (NP) cell feedback in IVDD, and impaired regenerative support in aging muscle in SP. We discuss how macrophage functional states are shaped by transcriptional and epigenetic regulation, immunometabolic rewiring, inflammatory signaling, autophagy and organelle quality control, and local niche-derived cues. Therapeutic strategies are then evaluated according to whether they interrupt upstream niche stress, redirect inflammatory and metabolic decoding, restore quality-control capacity, or reshape macrophage-mediated tissue communication. Finally, we propose that macrophage-targeted therapy should be assessed through a hierarchy of evidence, progressing from marker changes to functional reprogramming, macrophage-causal validation, and disease-specific structural or functional improvement. This framework may help convert macrophage plasticity from a broad immunological concept into a more precise, testable, and disease-adapted therapeutic strategy for musculoskeletal degeneration. The translational potential of this article: This Review provides a disease-niche-adapted framework for evaluating macrophage reprogramming in degenerative musculoskeletal diseases. By linking disease-specific macrophage tasks with regulatory mechanisms, therapeutic entry points, causal validation, delivery feasibility, and tissue-relevant endpoints, this framework may help guide both the design and translational assessment of macrophage-targeted interventions for musculoskeletal degeneration.
SN - 2214-031X
SN - 2214-0328
ER -